Published in Int J Radiat Oncol Biol Phys on December 14, 2010
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Volumetric-modulated arc therapy vs. c-IMRT in esophageal cancer: a treatment planning comparison. World J Gastroenterol (2012) 0.96
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf (2011) 0.92
Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol (2013) 0.89
Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res (2014) 0.87
Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2013) 0.86
Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res (2014) 0.86
Preliminary analysis of risk factors for late rectal toxicity after helical tomotherapy for prostate cancer. J Radiat Res (2013) 0.85
Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer. Radiat Oncol (2013) 0.79
Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med (2014) 0.78
Acute anal toxicity after whole pelvic radiotherapy in patients with asymptomatic haemorrhoids: identification of dosimetric and patient factors. Br J Radiol (2015) 0.77
Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer. Radiat Oncol (2016) 0.75
Radical radiotherapy for high-risk prostate cancer in older men. Oncologist (2012) 0.75
Dosimetric impact of different bladder and rectum filling during prostate cancer radiotherapy. Radiat Oncol (2016) 0.75
Parametrized rectal dose and associations with late toxicity in prostate cancer radiotherapy. Br J Radiol (2015) 0.75
Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol (2016) 0.75
Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases. Radiat Oncol (2017) 0.75
A comparative dosimetric study of volumetric-modulated arc therapy vs. fixed field intensity-modulated radiotherapy in postoperative irradiation of stage IB-IIA high-risk cervical cancer. Oncol Lett (2015) 0.75
Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med (2017) 0.75
Effect of modern, high-quality prostate intensity-modulated radiation therapy on outcome: Evidence from a community radiation oncology program. Mol Clin Oncol (2017) 0.75
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol (2010) 4.39
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Quantitative tumor oxymetric images from 4D electron paramagnetic resonance imaging (EPRI): methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magn Reson Med (2003) 3.02
Evaluation of sparse-view reconstruction from flat-panel-detector cone-beam CT. Phys Med Biol (2010) 2.95
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol (2007) 2.44
Spin echo spectroscopic electron paramagnetic resonance imaging. Magn Reson Med (2006) 2.02
Electron paramagnetic resonance oxygen image hypoxic fraction plus radiation dose strongly correlates with tumor cure in FSa fibrosarcomas. Int J Radiat Oncol Biol Phys (2008) 1.84
Region of interest reconstruction from truncated data in circular cone-beam CT. IEEE Trans Med Imaging (2006) 1.55
Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology (2013) 1.40
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol (2008) 1.28
External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys (2010) 1.21
The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol (2010) 1.18
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol (2012) 1.17
Exact reconstruction of volumetric images in reverse helical cone-beam CT. Med Phys (2008) 1.13
External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys (2009) 1.10
Immobilization Using Dental Material Casts Facilitates Accurate Serial and Multimodality Small Animal Imaging. Concepts Magn Reson Part B Magn Reson Eng (2008) 1.09
Receiver operating characteristic analysis: a general tool for DNA array data filtration and performance estimation. Genomics (2003) 1.08
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics (2010) 1.08
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol (2013) 1.03
EPR oxygen images predict tumor control by a 50% tumor control radiation dose. Cancer Res (2013) 1.03
Region-of-interest image reconstruction in circular cone-beam microCT. Med Phys (2007) 1.02
Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis. BMC Cancer (2003) 0.99
Where it's at really matters: in situ in vivo vascular endothelial growth factor spatially correlates with electron paramagnetic resonance pO2 images in tumors of living mice. Mol Imaging Biol (2011) 0.98
A Gaussian mixture model for definition of lung tumor volumes in positron emission tomography. Med Phys (2007) 0.98
The development and testing of a digital PET phantom for the evaluation of tumor volume segmentation techniques. Med Phys (2008) 0.96
Lung texture in serial thoracic CT scans: assessment of change introduced by image registration. Med Phys (2012) 0.96
Characterization of response to radiation mediated gene therapy by means of multimodality imaging. Magn Reson Med (2009) 0.94
The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer (2010) 0.93
A hybrid approach to reducing computed tomography metal artifacts in intracavitary brachytherapy. Brachytherapy (2005) 0.92
Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2012) 0.91
External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys (2010) 0.91
Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: a report of total setup error, required PTV expansion, and dosimetric implications. Radiother Oncol (2011) 0.90
Region-of-interest image reconstruction with intensity weighting in circular cone-beam CT for image-guided radiation therapy. Med Phys (2009) 0.89
Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection? Cancer (2008) 0.88
Reduction of image artifacts in mice by bladder flushing with a novel double-lumen urethral catheter. Mol Imaging (2006) 0.87
Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis. Am J Clin Oncol (2010) 0.87
A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol (2010) 0.86
High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging (2011) 0.86
Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis. Brachytherapy (2009) 0.86
Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol (2012) 0.84
Reduction of computed tomography metal artifacts due to the Fletcher-Suit applicator in gynecology patients receiving intracavitary brachytherapy. Brachytherapy (2003) 0.83
Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol (2008) 0.82
Characterization of a novel phantom for three-dimensional in vitro cell experiments. Phys Med Biol (2009) 0.81
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiat Oncol (2012) 0.81
Radiotherapeutic strategies in the management of low-risk prostate cancer. ScientificWorldJournal (2010) 0.81
Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. Cancer (2013) 0.80
Validation of normal tissue complication probability predictions in individual patient: late rectal toxicity. Int J Radiat Oncol Biol Phys (2012) 0.79
Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer (2009) 0.79
Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. Onco Targets Ther (2013) 0.79
Effects of aspirin on cancer initiation and progression. Expert Rev Anticancer Ther (2013) 0.78
Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med (2014) 0.78
Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans. Med Dosim (2004) 0.78
ACR Appropriateness Criteria Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol (2017) 0.78
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys (2009) 0.77
HiSStology: high spectral and spatial resolution magnetic resonance imaging detection of vasculature validated by histology and micro-computed tomography. Mol Imaging (2011) 0.76
High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys (2012) 0.76
Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer. Technol Cancer Res Treat (2007) 0.76
Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.76
The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res (2007) 0.75
Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access J Urol (2011) 0.75
Gastrointestinal Cancers-Changing the Standard for Rectal Cancer and Establishing a New Standard for Liver Tumors. Int J Radiat Oncol Biol Phys (2016) 0.75
Key New Studies in Gastric and Esophageal Cancer. Int J Radiat Oncol Biol Phys (2015) 0.75
Gastrointestinal Cancers: Timing Is Everything. Int J Radiat Oncol Biol Phys (2017) 0.75
Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race. Am J Clin Oncol (2014) 0.75
Randomized trials and new directions in gastrointestinal cancer. Int J Radiat Oncol Biol Phys (2015) 0.75
Validation of temporal optimization effects for a single fraction of radiation in vitro. Int J Radiat Oncol Biol Phys (2009) 0.75
High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol (2017) 0.75
Dosimetric quality endpoints for low-dose-rate prostate brachytherapy using biological effective dose (BED) vs. conventional dose. Med Dosim (2003) 0.75